⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INSM News
Insmed, Inc.
Insmed Provides Clinical and Business Update
prnewswire.com
INSM
Antibody Optimization Service Market Set to Reach USD 6.07 Billion by 2034, Growing at an 8.45% CAGR Amid Advances in Gene-Editing Technologies
globenewswire.com
ABBV
BMY
GILD
AMGN
AZN
LLY
BIIB
REGN
VRTX
XBI
IBB
CRSP
EDIT
NTLA
ABCL
NVS
MRK
PFE
JNJ
GSK
SNY
BTAI
INSM
Annual Changes to the Nasdaq-100 Index®
globenewswire.com
NDAQ
ALNY
FER
INSM
MPWR
STX
WDC
BIIB
CDW
GFS
LULU
ON
TTD
Questex’s Chief Medical Officer Summit 360° Announces 2026 Agenda and Keynotes
globenewswire.com
INSM
BIIB
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
prnewswire.com
INSM
Instem Unveils New Global Headquarters in Boston, MA
businesswire.com
INSM
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
globenewswire.com
SNGX
PFE
MRK
BMY
INSM
Qiming Venture Partners Donates HK$3 Million to Tai Po Wang Fuk Court Aid Fund for Post-Fire Recovery
prnewswire.com
XOM
MSFT
GOOG
AMZN
NVDA
TSLA
META
BABA
JD
PDD
NTES
BILI
ZNH
RRBT
HSAI
UBOT
WRDE
HSTR
INST
UNIS
GEL
TIGR
ZLAB
CNBC
SRCH
APM
SMY
AMDX
SCNL
ASPB
YXT
INSM
MLTX
LNV
STEF
European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
prnewswire.com
INSM
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
prnewswire.com
INSM